Our aim was to analyze the association of HSPA1B genotypes and treatment response measured by the changes of psychopathology and neurocognitive symptoms in patients with first-episode psychosis (FEP) after 18 months of treatment. A sample of 159 patients with FEP admitted at two Croatian psychiatric hospitals in the period between year 2014 and year 2017 was assessed at baseline and after 18 months of follow-up with Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS) and a battery of neurocognitive tests. Associations of scale and test results with HSPA1B polymorphic locus rs1061581 were analyzed using the general linear model. The carriers of the AA genotype showed the highest improvement in CDSS and RAVLT A test after the 18-month follow-up. Concordantly, we found significantly higher improvement assessed with the CDSS, RAVLT A, RAVLT A 30' and positive PANSS scales in the not-GG (AA/AG) group compared with the GG group. Our study suggests that HSPA1B rs1061581variants may moderate treatment response in FEP measured with changes of psychopathology and neurocognitive test results.

中文翻译：

---

HSPA1B 基因型与首发精神病患者的精神病理学和神经认知的关联：一项为期 18 个月的纵向随访研究。

我们的目的是分析 HSPA1B 基因型与治疗反应的关联，通过治疗 18 个月后首发精神病（FEP）患者的精神病理学和神经认知症状的变化来衡量。对 2014 年至 2017 年期间在两家克罗地亚精神病院收治的 159 名 FEP 患者的样本进行了基线评估和 18 个月的随访，采用阳性和阴性综合征量表 (PANSS)、卡尔加里精神分裂症抑郁量表 ( CDSS）和一系列神经认知测试。使用一般线性模型分析规模和测试结果与 HSPA1B 多态性基因座 rs1061581 的关联。在 18 个月的随访后，AA 基因型的携带者在 CDSS 和 RAVLT A 测试中表现出最大的改善。一致地，我们发现与 GG 组相比，非 GG (AA/AG) 组的 CDSS、RAVLT A、RAVLT A 30' 和阳性 PANSS 量表评估的改善显着更高。我们的研究表明，随着精神病理学和神经认知测试结果的变化，HSPA1B rs1061581 变体可能会减轻 FEP 的治疗反应。